SARS-CoV-2 Recombinant Protein Vaccine, strain B.1.351 (Sanofi/Glaxosmithkline)

N/A

Report date: 2024/03/21 20:00:29

Base Information

Drug NameSARS-CoV-2 Recombinant Protein Vaccine, strain B.1.351 (Sanofi/Glaxosmithkline)
Drug Alias NameVaccin SP/GSK, CoV2 preS dTM-AS03 adjuvanted vaccine, strain B.1.351VidPrevtyn Beta
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Genetically engineered subunit vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2022/11/10
Country/TerritoryUnited StatesNew ZealandAustralia +[8] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesSanofi PasteurGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcSanofi PasteurNational Institute Of Allergy And Infectious Diseases (Niaid)
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A